Propranolol treatment of portal hypertension in cirrhosis patients is better the higher the untreated pressure: a single-centre prospective experience

References

• de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167–76.
   PubMed Web of Science ®Google Scholar
• Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol 2009;6:573–82.
   PubMed Web of Science ®Google Scholar
• Merkel C, Bolognesi M, Sacerdoti D, Bombonato G, Bellini B, Bighin R, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology 2000;32:930–4.
   PubMed Web of Science ®Google Scholar
• Tandon P, Saez R, Berzigotti A, Abraldes JG, Garcia-Pagan JC, Bosch J. A specialized, nurse-run titration clinic: a feasible option for optimizing beta-blockade in non-clinical trial patients. Am J Gastroenterol 2010;105:1917–21.
   PubMed Web of Science ®Google Scholar
• Merkel C, Montagnese S. Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as guidance for prophylaxis and treatment of bleeding and re-bleeding? Yes! Eur J Intern Med 2011;22:1–4.
   PubMed Web of Science ®Google Scholar
• Villanueva C, Lopez-Balaguer JM, Aracil C, Kolle L, Gonzales B, Minana J, et al. Maintenance of hemodynamic response to treatment for portal hypertension and influence on complications of cirrhosis. J Hepatol 2004;40:757–65.
   PubMed Web of Science ®Google Scholar
• Keiding S, Vilstrup H. Intrahepatic heterogeneity of hepatic venous pressure gradient in human cirrhosis. Scand J Gastroenterol 2002;37:960–4.
   PubMed Web of Science ®Google Scholar
• Albillos A, Banares R, Gonzalez M, Ripoll C, Gonzalez R, Catalina MV, et al. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol 2007;102:1116–26.
   PubMed Web of Science ®Google Scholar
• Feu F, Garcia-Pagan JC, Bosch J, Luca A, Teres J, Escorsell A, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056–9.
   PubMed Web of Science ®Google Scholar
• Villanueva C, Balanzo J, Novella MT, Soriano G, Sainz S, Toras X, et al. Nadolol plus isosorbide mononitrate compared with sclerotherapy for the prevention of variceal rebleeding. N Engl J Med 1996;334:1624–9.
   PubMed Web of Science ®Google Scholar
• Thalheimer U, Bosch J, Burroughs AK. How to prevent varices from bleeding: shades of grey–the case for nonselective beta blockers. Gastroenterology 2007;133:2029–36.
   PubMed Web of Science ®Google Scholar
• Turnes J, Garcia-Pagan JC, Abraldes JG, Hernandez-Guerra M, Dell'Era A, Bosch J. Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol 2006;101:506–12.
   PubMed Web of Science ®Google Scholar
• Abraldes JG, Tarantino I, Turnes J, Garcia-Pagan JC, Rodes J, Bosch J. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis. Hepatology 2003;37:902–8.
   PubMed Web of Science ®Google Scholar
• Suk KT, Kim MY, Park DH, Kim KH, Jo KW, Hong JH, et al. Effect of propranolol on portal pressure and systemic hemodynamics in patients with liver cirrhosis and portal hypertension: a prospective study. Gut Liver 2007;1:159–64.
   PubMed Web of Science ®Google Scholar
• Serste T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 2010;52:1017–22.
   PubMed Web of Science ®Google Scholar
• Wong F, Salerno F. Beta-blockers in cirrhosis: friend and foe? Hepatology 2010;52:811–13.
   PubMed Web of Science ®Google Scholar
• McCormick PA, Patch D, Greenslade L, Chin J, McIntyre N, Burroughs AK. Clinical vs haemodynamic response to drugs in portal hypertension. J Hepatol 1998;28:1015–19.
   PubMed Web of Science ®Google Scholar
• Bañares R, Moitinho E, Matilla A, Garcia-Pagan JC, Lampreave JI, Piera C, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology 2002;36:1367–73.
   PubMed Web of Science ®Google Scholar
• Jepsen P, Ott P, Andersen PK, Vilstrup H. The clinical course of alcoholic cirrhosis: effects of hepatic metabolic capacity, alcohol consumption, and hyponatremia – a historical cohort study. BMC Res Notes 2012;18:509.
   Google Scholar
• Augustin S, Gonzalez A, Badia L, Millan L, Gelabert A, Romero A, et al. Long-term follow-up of hemodynamic responders to pharmacological therapy after variceal bleeding. Hepatology 2012;56:706–14.
   PubMed Web of Science ®Google Scholar
• Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosbers CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001;33:464–70.
   PubMed Web of Science ®Google Scholar
• Tygstrup N. Determination of the hepatic elimination capacity (Lm) of galactose by single injection. Scand J Clin Lab Invest Suppl 1966;18:118–25.
   PubMedGoogle Scholar